NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,075.63 mln
Float126 mln
Earnings Date07/30/2026
EPS
2.16
Solid
P / E
7.62
Undervalued
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
7.94
Highly suspicious
Relative Strength
66
/ 100
Outperforming
Debt / Equity
0.12
Very low leverage
Business Description
Aurinia Pharmaceuticals is a Canadian company focused on treating patients with serious autoimmune conditions that currently have few effective options. Its main product, LUPKYNIS, is a pill taken by mouth to help adults manage lupus nephritis, a severe kidney disease caused by lupus. The company is also working on an experimental drug called aritinercept, which targets two proteins believed to drive autoimmune disease. Founded in 1993 and based in Edmonton, Aurinia sells its treatments primarily in the United States and Japan.
